Tag: genomics
-
Infant Gut Microbiome Biomarker Study Underway
A clinical study has begun analyzing infants’ stool samples to determine the characteristics of healthy microbial communities in young children.
-
Univ. Labs Ink Licensing Deals for Covid-19 Tests
Two companies agreed to license technologies from academic labs in the U.S. and U.K. for developing faster and more sensitive at-home tests for Covid-19 infections.
-
Patent Issued for Anti-Bacterial Viruses with Crispr Payloads
A biotechnology company received a patent for its engineered viruses to deliver gene-edited treatments to combat bacterial infections in the microbiome.
-
Biotech Start-Up Demonstrates Cancer Therapy, Raises $6.4M
A new biotechnology company demonstrated in lab mice its therapy for glioblastoma, an aggressive brain cancer, that overcomes limitations of current treatments.
-
Biotechs Discover Antimicrobial Peptide for Food Safety
Two biotechnology companies say they discovered a peptide molecule with antimicrobial properties for faster identification and containment of food contamination outbreaks.
-
Small Biz Grant Funds Non-Viral Gene Editing Delivery
National Institutes of Health is financing a delivery method for gene-editing therapies to blood-forming stem cells with natural lipid bubbles instead of viruses.
-
Ginkgo Acquires Biomaterials Maker as Industry Consolidates
A developer of synthetic biology tools and components is acquiring a biological materials developer for its automation assets as the biotechnology industry consolidates.
-
Trial Okayed for Engineered Cell Cancer Therapy
A clinical trial is set to begin testing engineered immune-system cells designed to precisely target and infiltrate cancerous tumors without other potentially toxic proteins.
-
NIH Funding Engineered Phage Screening Device
National Institutes of Health is funding initial development of a microfluidic device that tests engineered viruses for their ability to kill disease-causing bacteria.
-
Precision Protein Design Start-Up Gains $40M in Early Funds
A start-up company designing and testing precise proteins within live animals to speed creation of new therapeutics is raising $40 million in its first venture round.